JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.91 CNY | +0.48% |
|
+2.67% | -40.58% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.08B 15.1B 174B |
|---|---|---|---|---|---|
| Net income 2024 * | 329M 2.38B 27.46B | Net income 2025 * | 413M 2.99B 34.46B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
6.33
x | P/E ratio 2025 * |
5.05
x | Employees | 451 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 22.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.48% | ||
| 1 week | +2.67% | ||
| Current month | -10.01% | ||
| 1 month | -8.30% | ||
| 3 months | -26.57% | ||
| 6 months | -46.15% | ||
| Current year | -40.58% |
1 week
16.22
17.10
1 month
15.9319.40
Current year
15.0128.65
1 year
15.0152.41
3 years
15.0179.42
5 years
15.0179.42
10 years
15.0179.42
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hui Zhang
CEO | Chief Executive Officer | 66 | 27/23/27 |
Qiang Huang
DFI | Director of Finance/CFO | 44 | 01/21/01 |
Jun Yu
CHM | Chairman | 55 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rong Shao
BRD | Director/Board Member | 62 | 15/20/15 |
Liang Bin Zhang
BRD | Director/Board Member | 49 | 01/15/01 |
Jian Qiang Guan
BRD | Director/Board Member | 62 | 15/20/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 16.91 | +0.48% | 528,259 |
| 25/24/25 | 16.83 | +2.43% | 580,430 |
| 24/24/24 | 16.43 | -0.96% | 490,015 |
| 23/24/23 | 16.59 | +0.61% | 428,047 |
| 22/24/22 | 16.49 | +0.12% | 564,988 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
Sector
Pharmaceuticals
Calendar
05/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
16.91
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.58% | 287M | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +55.70% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.02% | 8.71B |
- Stock Market
- Equities
- 688670 Stock
